Prevalence of asymptomatic brain metastases in metastatic nonsquamous nonsmall cell lung cancer: Treatment implications for resource-constrained settings.

IF 0.9 4区 医学 Q4 ONCOLOGY
Indian journal of cancer Pub Date : 2024-01-01 Epub Date: 2023-12-07 DOI:10.4103/ijc.IJC_878_20
Shubham Shukla, Kuruswamy Thurai Prasad, Chirag Kamal Ahuja, Valliappan Muthu, Navneet Singh
{"title":"Prevalence of asymptomatic brain metastases in metastatic nonsquamous nonsmall cell lung cancer: Treatment implications for resource-constrained settings.","authors":"Shubham Shukla, Kuruswamy Thurai Prasad, Chirag Kamal Ahuja, Valliappan Muthu, Navneet Singh","doi":"10.4103/ijc.IJC_878_20","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Brain metastases (BM) are common in metastatic nonsmall cell lung cancer (NSCLC). However, routine neuroimaging in asymptomatic patients with metastatic NSCLC is controversial as there is no conclusive evidence of benefit from the detection and treatment of asymptomatic BM. Herein, we evaluated the prevalence of asymptomatic BM and its treatment implications in a resource-limited setting.</p><p><strong>Methods: </strong>Consecutive patients with newly diagnosed, treatment-naïve, metastatic, nonsquamous NSCLC (NS-NSCLC) were included. Subjects who already had clinical or radiological features suggestive of BM were excluded from the study. All eligible subjects underwent contrast-enhanced magnetic resonance imaging (MRI) of the brain. Management of the detected BM was at the discretion of the treating clinicians.</p><p><strong>Results: </strong>Among 809 subjects who were screened, 100 (12.4%) were included in the study and underwent MRI. BM was present in 30 (30%) of the subjects and absent in the remaining 70 subjects. A majority of BM were multiple (70%), involved the frontal lobe commonly (73.3%), and had a mean (standard deviation) size of 13.2 (7.3) mm. Detection of BM resulted in a treatment alteration in 17 (17%) of the study subjects (brain irradiation, n = 17, change in targeted therapy, n = 3) with BM. There was no difference in survival of patients who underwent treatment alteration for management of BM compared to those who did not ( P = 0.132).</p><p><strong>Conclusions: </strong>About one-third of patients with metastatic NS-NSCLC had BM in MRI despite the absence of symptoms. Despite treatment of the majority of the patients with BM with brain irradiation, there was no demonstrable survival benefit. Hence, we conclude that although routine neuroimaging of asymptomatic patients with newly diagnosed metastatic NSCLC may result in treatment alteration (primarily brain irradiation) in a small proportion of patients, it may not influence outcomes in resource-constrained settings.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":"29-36"},"PeriodicalIF":0.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian journal of cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/ijc.IJC_878_20","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/7 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Brain metastases (BM) are common in metastatic nonsmall cell lung cancer (NSCLC). However, routine neuroimaging in asymptomatic patients with metastatic NSCLC is controversial as there is no conclusive evidence of benefit from the detection and treatment of asymptomatic BM. Herein, we evaluated the prevalence of asymptomatic BM and its treatment implications in a resource-limited setting.

Methods: Consecutive patients with newly diagnosed, treatment-naïve, metastatic, nonsquamous NSCLC (NS-NSCLC) were included. Subjects who already had clinical or radiological features suggestive of BM were excluded from the study. All eligible subjects underwent contrast-enhanced magnetic resonance imaging (MRI) of the brain. Management of the detected BM was at the discretion of the treating clinicians.

Results: Among 809 subjects who were screened, 100 (12.4%) were included in the study and underwent MRI. BM was present in 30 (30%) of the subjects and absent in the remaining 70 subjects. A majority of BM were multiple (70%), involved the frontal lobe commonly (73.3%), and had a mean (standard deviation) size of 13.2 (7.3) mm. Detection of BM resulted in a treatment alteration in 17 (17%) of the study subjects (brain irradiation, n = 17, change in targeted therapy, n = 3) with BM. There was no difference in survival of patients who underwent treatment alteration for management of BM compared to those who did not ( P = 0.132).

Conclusions: About one-third of patients with metastatic NS-NSCLC had BM in MRI despite the absence of symptoms. Despite treatment of the majority of the patients with BM with brain irradiation, there was no demonstrable survival benefit. Hence, we conclude that although routine neuroimaging of asymptomatic patients with newly diagnosed metastatic NSCLC may result in treatment alteration (primarily brain irradiation) in a small proportion of patients, it may not influence outcomes in resource-constrained settings.

转移性非鳞状非小细胞肺癌中无症状脑转移的发生率:对资源有限地区的治疗意义。
背景:脑转移(BM)在转移性非小细胞肺癌(NSCLC)中很常见。然而,对无症状的转移性 NSCLC 患者进行常规神经影像学检查尚存在争议,因为没有确凿证据表明检测和治疗无症状脑转移瘤对患者有益。在此,我们在资源有限的环境中评估了无症状脑干胶质瘤的患病率及其对治疗的影响:方法:纳入新诊断、治疗无效、转移性非鳞状 NSCLC(NS-NSCLC)患者。临床或放射学特征提示BM的受试者被排除在研究之外。所有符合条件的受试者都接受了脑部对比增强磁共振成像(MRI)检查。对检测出的 BM 的处理由主治临床医生决定:在接受筛查的 809 名受试者中,有 100 人(12.4%)被纳入研究并接受了磁共振成像检查。其中 30 名受试者(30%)存在骨水泥瘤,其余 70 名受试者不存在骨水泥瘤。大多数 BM 为多发性(70%),通常累及额叶(73.3%),平均(标准差)大小为 13.2(7.3)毫米。在发现 BM 的研究对象中,有 17 人(17%)因 BM 而改变了治疗方法(脑部照射,17 人;改变靶向治疗,3 人)。因BM而改变治疗方案的患者与未改变治疗方案的患者在生存率上没有差异(P = 0.132):结论:约三分之一的转移性NS-NSCLC患者尽管没有症状,但在磁共振成像中发现了BM。结论:约有三分之一的转移性NS-NSCLC患者尽管没有症状,但在磁共振成像中发现了BM,尽管对大多数有BM的患者进行了脑部照射治疗,但并没有明显的生存获益。因此,我们得出结论:虽然对无症状的新诊断转移性 NSCLC 患者进行常规神经影像学检查可能会导致一小部分患者改变治疗方案(主要是脑部照射),但在资源有限的情况下,这可能不会影响治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Indian journal of cancer
Indian journal of cancer Medicine-Oncology
CiteScore
1.40
自引率
0.00%
发文量
67
审稿时长
>12 weeks
期刊介绍: Indian Journal of Cancer (ISSN 0019-509X), the show window of the progress of ontological sciences in India, was established in 1963. Indian Journal of Cancer is the first and only periodical serving the needs of all the specialties of oncology in India.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信